UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again

FDA Reverses Stance, UniQure to Submit BLA for Huntington's Gene Therapy

uniQure intends to submit a Biologics License Application (BLA) for its Huntington’s disease gene therapy, AMT-130, in the third quarter. This follows the FDA's agreement that three-year data from uniQure’s Phase 1/2 trial are sufficient to support accelerated approval. This decision marks a significant reversal from the FDA's previous stance, which had insisted on an additional sham surgery-controlled Phase 3 trial. The agency is now considering a standard-of-care control for the confirmatory study. If approved, AMT-130, which slowed disease progression by 75% after three years, would be the first genetic treatment for Huntington’s disease.

• The FDA has reversed its previous requirement for a sham surgery-controlled Phase 3 trial for AMT-130, now agreeing that three-year data from uniQure's Phase 1/2 trial can support an accelerated BLA. The agency is also considering a standard-of-care control for the confirmatory study, addressing ethical concerns raised by experts and patient advocacy groups regarding sham surgery.
• The decision is supported by positive three-year data from uniQure's Phase 1/2 trial, which demonstrated that AMT-130 slowed the progression of Huntington's disease by 75%. This efficacy data is now deemed adequate by the FDA to serve as primary evidence for the BLA submission, paving the way for the potential first genetic treatment for the condition.
• This development follows a period of regulatory uncertainty and previous disagreements with the FDA, including criticism from former FDA commissioner Marty Makary. The update is seen as a sign of renewed regulatory flexibility, particularly after Makary's departure, aligning uniQure with other biotechs that have recently reported positive regulatory interactions.

Addressing the Unmet Need in Huntington's Disease

Despite decades of research, Huntington's disease remains without any approved disease-modifying therapy, leaving clinicians limited to symptomatic management that addresses quality of life but does not alter disease progression. The treatment landscape is further complicated by the multifactorial pathogenic mechanisms underlying HD, the challenges of CNS drug delivery, and a historically high rate of clinical trial attrition.

• Absence of disease-modifying treatment: No therapy has been approved to slow, halt, or reverse HD progression. Current management is restricted to symptomatic relief — such as reducing chorea severity — with no clinical guidelines to guide rehabilitation, and very few robust studies informing best practice in this area.

• Failed and inconclusive clinical trials: Promising mechanistic candidates have not translated to clinical benefit. A randomized, double-blind trial of riluzole (an antiexcitotoxic agent) in 537 patients over three years demonstrated no neuroprotective or symptomatic benefit, with median combined score changes of 13.7 (placebo) versus 14.3 (riluzole) and no statistically significant intergroup difference (p = 0.93).

• Unverified efficacy and safety of emerging gene therapy modalities: Huntingtin-lowering strategies — including antisense oligonucleotides (ASOs), RNA interference, zinc finger proteins, and CRISPR-Cas9 techniques — remain investigational. Long-term safety, tolerability, and efficacy have yet to be established, and many approaches require direct neurosurgical intervention for CNS delivery, given their inability to cross the blood-brain barrier via systemic administration.

• Unsatisfactory outcomes from cell-based approaches: Fetal neural transplantation has been evaluated in both preclinical and clinical settings, but efficacy has not been satisfactory. Stem cell-based therapies are only beginning to enter human trials, and significant research is still required to establish their feasibility, safety, and efficacy in HD.

• Complex and incompletely understood pathogenesis: HD is increasingly recognized as arising from multiple converging pathogenic processes, including somatic instability of the mutant HTT CAG repeat tract, which produces diverse downstream consequences. The precise function of the huntingtin protein itself also remains incompletely characterized, complicating rational therapeutic targeting.

• Diagnostic challenges compounding clinical management: Establishing or confirming an HD diagnosis can be difficult, particularly when patients with known or suspected HD present with acute neurological deterioration against a background of prominent cognitive impairment. Phenotypic overlap with other conditions has been associated with diagnostic delays and prolonged inpatient admissions.

Understanding AMT-130's Clinical Data

Early Phase I/II clinical data for AMT-130 indicate a favorable safety and tolerability profile in patients with Huntington's disease — the primary indication in which the therapy has been studied. AMT-130 is a one-time gene therapy utilizing an adeno-associated virus serotype 5 (AAV5) vector, administered via stereotactic intracerebral infusion into the caudate and putamen. While specific adverse event profiles and treatment-related discontinuation rates are not detailed in the currently available published literature, the overall safety signal observed across studied cohorts has been described as favorable.

Importantly, the safety data have emerged alongside encouraging early efficacy signals. In high-dose cohorts specifically, AMT-130 demonstrated reductions in neurofilament light chain levels — a recognized biomarker of neuronal injury — as well as stabilization of motor and functional decline. Together, these findings suggest a potential slowing of disease progression, lending biological plausibility to the clinical observations and reinforcing the tolerability narrative.

Nonetheless, the current evidence base carries meaningful limitations. Long-term efficacy data and broader clinical validation remain outstanding requirements before definitive conclusions can be drawn regarding the therapy's benefit-risk profile. The Phase I/II dataset, while promising, represents early-stage evidence, and continued follow-up across larger, more diverse cohorts will be essential to fully characterize AMT-130's safety and durability of effect.

The Evolving Landscape for Huntington's Disease Therapies

The treatment landscape for Huntington's disease (HD) over the past five years has been defined as much by high-profile setbacks as by emerging investigational strategies. Most notably, recent clinical trial failures of antisense oligonucleotide (ASO) candidates have underscored the difficulty of translating promising preclinical mechanisms into clinical benefit, and as of the most recently published data, no disease-modifying therapy has received regulatory approval for HD. This absence of approved agents extends to the symptomatic domain as well: a double-blind, placebo-controlled, randomized crossover trial evaluating dextromethorphan/quinidine (DM/Q) 20/10 mg (NUEDEXTA) for irritability in HD enrolled 20 participants across a 13-week protocol and found that both the active arm and placebo reduced mean Irritability Scale and PBA-s irritability subscale scores — by 32% vs. 27.5% and 42% vs. 33%, respectively — with no statistically significant between-group differences in irritability, motor, behavioral, or cognitive outcomes. Similarly, ceftriaxone, a beta-lactam antibiotic supported by more than 100 preclinical studies demonstrating attenuation of behavioral manifestations in HD models, failed to show a survival benefit over placebo in the one large-scale clinical trial conducted, albeit in an ALS population rather than HD specifically.

Against this backdrop of clinical disappointment, nucleic acid–based and gene-silencing approaches continue to advance as the field's most active investigational frontier. Clinical trials using nucleic acid therapeutics to silence the causative HTT gene in polyglutamine (polyQ) diseases have been conducted, though none have achieved approval. Preclinically, an acyclic serinol nucleic acid (SNA)-modified small interfering RNA (siRNA) targeting CAG repeats demonstrated selective allele silencing following intracerebroventricular administration in mouse models, suppressing polyQ protein expression without affecting wild-type counterparts — a meaningful specificity advance for this class. Gene therapeutic silencing strategies for gain-of-toxic-function mutations, while less prevalent than gene replacement approaches, are also being actively developed. In parallel, a novel in-silico fragment scanning approach identified the small molecule GLYN122, which directly binds and reduces mutant huntingtin (mHTT), induces neuronal autophagy in vitro, and improved motor symptoms and reduced mHTT burden in the cortex and striatum of the R6/2 mouse model, positioning it as an early-stage preclinical candidate. Cell replacement strategies — including fetal neural tissue transplantation and stem cell–based approaches aimed at reconstituting the desired striatal neuron phenotype or supplying trophic support — have been evaluated in both animal models and limited human trials, though clinical results have been less compelling.

Infrastructure development has meaningfully supported the field's ability to interrogate these emerging modalities. The Enroll-HD platform, operational since July 2012 across 159 clinical sites in 21 countries on four continents, has recruited nearly 25,000 participants, generating a large longitudinal clinical database paired with biosamples that facilitates both observational research and recruitment into interventional trials. Additional exploratory avenues include modulation of the adenosine system, identified as a potentially novel therapeutic axis for HD, as well as nutraceutical candidates — including curcumin, resveratrol, epigallocatechin-3-gallate (EGCG), coenzyme Q10, and omega-3 fatty acids — which have demonstrated neuroprotective signals in human clinical settings through proposed mechanisms spanning antioxidant activity, anti-inflammatory effects, mitochondrial homeostasis, autophagy regulation, and neurogenesis promotion. Collectively, the past five years reflect a field in active recalibration: absorbing the lessons of failed trials while advancing a diversified portfolio of genetic, small-molecule, and cellular strategies toward human testing.

A New Regulatory Path for Huntington's Gene Therapy

The recent announcement regarding uniQure's AMT-130 marks a significant inflection point in the quest for effective treatments for Huntington's disease (HD). The FDA's willingness to consider accelerated approval based on three-year Phase 1/2 data, reversing its earlier stance, signals a pragmatic and patient-centric approach to drug development in areas of profound unmet medical need. This flexibility is particularly crucial for a devastating neurodegenerative disorder like HD, where current management is largely symptomatic.

AMT-130 represents a novel, disease-modifying strategy, utilizing an AAV5 vector to deliver microRNA directly into the brain to reduce mutant huntingtin protein. Early clinical data, indicating a potential 75% slowing of disease progression, offers a beacon of hope for patients and their families. This regulatory shift could pave the way for other innovative gene therapies targeting complex neurological conditions, potentially accelerating their journey to market.

However, the path forward is not without its considerations. While accelerated approval offers a crucial early market entry, the long-term efficacy and safety profile of AMT-130 will require rigorous confirmation through a post-marketing study. The design of this confirmatory trial, now with a standard-of-care control, still presents logistical challenges in a rare disease population. Furthermore, the HD pipeline remains dynamic, with several other companies actively developing alternative therapeutic approaches. uniQure's ability to successfully navigate these post-approval requirements and demonstrate sustained benefit will be critical for solidifying AMT-130's position as a foundational treatment and for validating the broader potential of gene therapy in neurodegeneration. This development underscores the evolving landscape of regulatory science, balancing the urgency of patient need with the imperative for robust evidence.